Insider Activity to Watch: Cellular Biomedicine Group, Inc. $CBMG

euro-447209_1920

Cellular Biomedicine Group, Inc. (CBMG) insiders have most recently took part in a trading activity. On Dec 22, 2017 Yao Yihong, Chief Scientific Officer bought 4,167 shares having total worth of $50,004 at the price of $12 per share, following the transaction a total of 29,667 shares owned by Yao Yihong.

On the same day, Liu Tony, CEO, CFO bought 29,167 shares having total worth of $350,004 at the price of $12 per share, following the transaction a total of 139,167 shares owned by Liu Tony. Before this latest buy, Liu Tony purchased CBMG at 1 other times during the past twelve months, for a total investment of $68,300 at an average of $6.83 per share.

On the same day, Chan Andrew K, SVP Corp Bus Dev and Secretary bought 8,333 shares having total worth of $99,996 at the price of $12 per share, following the transaction a total of 154,090 shares owned by Chan Andrew K.

Furthermore, over the past 12 months , the stock was traded 1 times by insiders. an employee of the company was the buyer in 1 instances.

Shares of Cellular Biomedicine Group, Inc. (CBMG) traded down 4.95% on Dec 26, 2017, hitting $10.55. 20,024 shares of the company’s stock traded hands. Cellular Biomedicine Group, Inc. has a 52 week low of $5.3 and a 52 week high of $15. The company’s market cap is $202 million.

Cellular Biomedicine Group Inc is a Delaware corporation formerly known as EastBridge Investment Group Corporation. It was originally incorporated in the State of Arizona on June 25, 2001. The Company’s principal line of business is in the field of biomedicine. It is involved in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell technologies, which include, without limitation, TC-DC (tumor cell specific dendritic cells) for treatment of a broad range of cancers, haMPC (human adipose-derived mesenchymal progenitor cells) for treatment of joint disease, huMPC (human umbilical cord-derived mesenchymal progenitor cells), and MNP (human embryo-derived motor neuron precursor cells) and NP (human embryo-derived neuronal precursor cells) for treatment of central nervous system diseases. Its biomedicine business was founded in 2009 as a newly formed specialty biomedicine company by a team of seasoned Chinese-American executives, scientists and doctors. The Company has fully licensed and transferred technology from California Stem Cell to produce clinical-quality motor neuron and neuronal progenitor cells from human embryonic stem cells (hESC’s). It has built an intellectual property portfolio to fortify its freedom of operation within its specialties in the cellular biomedicine field. Its portfolio contains patents, trade secrets, and know-how. Its technology can be grouped based on origin of progenitor or stem cells into adipose, umbilical cord, bone marrow and embryo.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.